ScholarIQanswers from OpenAlex & ORCID
Andrew E. Petroll
ResearcherPublications, citations & collaboration network
Andrew E. Petroll is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Andrew E. Petroll have?
ScholarIQindexed works
Andrew E. Petroll has 72 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Andrew E. Petroll have?
ScholarIQcitation count
Andrew E. Petroll has 2,151 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Andrew E. Petroll?
ScholarIQh-index
Andrew E. Petroll has an h-index of 24 in OpenAlex.
What is the i10-index of Andrew E. Petroll?
ScholarIQi10-index
Andrew E. Petroll has an i10-index of 38 in OpenAlex.
What is the ORCID of Andrew E. Petroll?
ScholarIQorcid
The ORCID for Andrew E. Petroll is on the source record.
What is the OpenAlex record for Andrew E. Petroll?
ScholarIQopenalex
The OpenAlex for Andrew E. Petroll is on the source record.
What are the most-cited papers on Andrew E. Petroll?
ScholarIQmost cited works
PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists
Andrew E. Petroll, Jennifer L. Walsh, Jill Owczarzak, Timothy L. McAuliffe, Laura M. Bogart, Jeffrey A. Kelly
Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review
Benedikt Pleuhs, Katherine Quinn, Jennifer L. Walsh, Andrew E. Petroll, Steven A. John
Physician Awareness of Sexual Orientation and Preventive Health Recommendations to Men Who Have Sex With Men
Andrew E. Petroll, Katie E. Mosack
Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review
Madeline Dang, Ayden I. Scheim, Michelle Teti, Katherine Quinn, Meagan Zarwell, Andrew E. Petroll, Keith J. Horvath, Steven A. John
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer, Laura Salazar, Keith Henry, David M. Asmuth, David A. Wohl, Richard Gilson, Yongwu Shao, Ramin Ebrahimi, Stephanie Cox, Alexander Kintu, Christoph C Carter, Moupali Das, Jared M. Baeten, Diana M. Brainard, Gary Whitlock, Jason Brunetta, Gitte Kronborg, Christoph D. Spinner, Andrea Antinori, Vanessa Apea, David M. Asmuth, Ann Avery, Paul Benson, Colm Bergin, Mezgebe Berhe, Indira Brar, Cynthia Brinson, Jason Brunetta, Jeffrey H. Burack, Thomas L. Campbell, Michelle Cespedes, Amanda Clarke, Megan Coleman, J Coll, Manuel Crespo Casal, Catherine Creticos, Gordon Crofoot, Frederick Cruickshank, Éric Cua, Eric S. Daar, Joseph de Wet, Edwin DeJesus, Jorge Del Romero Guerrero, William D. Dinges, Susanne Doblecki‐Lewis, Taylor Donovan, Olamide Dosekun, Jason Flamm, Joel E. Gallant, Jan Gerstoft, Richard Gilson, Jay Gladstein, Robert M. Grant, Robert Grossberg, Bernhard Haas, Jason Halperin, William D. Hardy, C. Bradley Hare, Shawn Hassler, Richard L. Hengel, William Henry, Theo Hodge, Sybil Hosek, Chris Hurt, Michelle Iandiorio, Heiko Jessen, Stephen Kegg, Gabriele Knecht, Gitte Kronborg, Ivanka Krznaric, Anthony LaMarca, Carsten Schade Larsen, Olav Larsen, Adriano Lazzarin, Clifford Leen, Christopher Lucasti, Patrick Mallon, Sharon Mannheimer, Martin Markowitz, Claudia Martorell, Kenneth Mayer, Anthony Mills, Jean‐Michel Molina, Sheldon Morris, Karam Mounzer, Nneka Nwokolo, Onyema Ogbuagu, Olayemi Osiyemi, Andrew E. Petroll, Patrick Philibert, John Phoenix, G. Pialoux, Daniel Podzamczer, Frank A. Post, Maria Prins, Moti Ramgopal, Bruce Rashbaum, Iain Reeves